Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?

I. Bobkova, E. Kamyshova, T. Rudenko, E. Stavrovskaya, S. Moiseev,

2021

https://doi.org/10.1016/j.mehy.2020.109888

Цитирование

Об авторах

I. Bobkova
Sechenov First Moscow State Medical University, Moscow, Russian Federation
E. Kamyshova
T. Rudenko
E. Stavrovskaya
S. Moiseev

Название журнала

Том

Страницы

Ключевые слова

angiotensin converting enzyme 2; angiotensin receptor antagonist; dipeptidyl carboxypeptidase inhibitor; coronavirus disease 2019; disease severity; genetic polymorphism; genetic variability; human; Letter; lung disease; nonhuman; prognosis; protein expression; renin angiotensin aldosterone system; Severe acute respiratory syndrome coronavirus 2; virus entry; virus load; Betacoronavirus; Coronavirus infection; immune system; pandemic; severe acute respiratory syndrome; virus pneumonia; Betacoronavirus; Coronavirus Infections; Humans; Immune System; Pandemics; Pneumonia, Viral; Renin-Angiotensin System; Severe Acute Respiratory Syndrome

Издатель

Тип документа

Тип лицензии Creative Commons

Правовой статус документа

Источник